FDA Reviews AI Tool Designed to Predict Drug-Related Liver Damage

What's happening

The FDA is evaluating a new artificial intelligence tool designed to predict whether an experimental drug could cause liver damage before it reaches patients.

Liver toxicity is one of the most common reasons drugs fail during development or face regulatory problems after reaching the market.

What's changing / Business impact

If successful, the technology could help pharmaceutical companies identify safety problems earlier in development.

This could reduce costly failures, improve patient safety, and shorten development timelines.

Why this matters

Many promising drugs never reach patients because unexpected side effects appear during testing.

Liver damage is particularly important because the liver processes many medications and can be vulnerable to toxic effects.

If AI can reliably identify risky compounds early, companies may avoid spending years developing treatments that ultimately fail.

This is another example of how artificial intelligence is moving beyond administrative tasks and into core scientific research.